Mr. Speaker, the FDA Week announced on January 27 that the FDA Office of Criminal Investigations reportedly questioned some individuals about the data on ruptures of Mentor breast implants.
One of the two employees mentioned that the real rate of rupture of new implants was not reported to the FDA and that Mentor hid leakages by attributing them to various problems such as seal breakage, and so forth.
In view of these allegations, can the minister assure us that there will be an investigation of the special access program to prevent this type of implant from ruining the lives of thousands of women?